Modalis Gets Orphan Drug Designation for MDL-101 in LAMA2-CMD
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to MDL-101, a novel…